NCT02974699

Brief Summary

There is currently a critical gap in knowledge of how intestinal bacterial communities alter metabolic substrates available to the host thereby influencing central and enteric nervous system (CNS/ENS) neurotransmitter levels involved in regulating carbohydrate consumption in humans. Understanding these relationships is essential for developing strategies to improve blood glucose control and to reduce the risk of transitioning from prediabetes to type-2 diabetes (T2D). The investigators' long-term goal is to determine the biological underpinnings of behaviors that impact food intake and blood glucose control that contribute to the development of T2D. The objective of this proposal, which is an essential next step in attaining the investigators' long-term goals, is to determine how bacterial populations in the digestive system impact circulating tryptophan (TRP) and large neutral amino acid (LNAA) levels that regulate production of monoamine 5-hydroxytryptamine (5-HT, serotonin) in the ENS and in gastrointestinal system and the brain. The central hypothesis is that a reduced ratio of TRP producing (TRPp) to TRP consuming (TRPc) bacteria (decreased TRPp:TRPc ratio) in the gut will decrease TRP availability following a carbohydrate meal lowering the plasma TRP:LNAA ratio and resulting in less TRP for ENS/CNS production of 5HT. Further, dietary interventions that promote TRPp bacterial abundance within the gut will increase TRP availability to the host. The investigators will test the central hypothesis and, thereby, accomplish the overall objective for this project by pursuing the following specific aims: 1) Assess impact of divergent microbiota on plasma TRP:LNAA ratio in response to acute carbohydrate consumption, and 2) Assess the impact of dietary supplementation with resistant starch (RS) on gut microbiota and circulating TRP:LNAA ratio. During Aim 1, stool samples will be collected from healthy participants. Participants will be stratified based on gut TRPp:TRPc ratio and the response to an acute meal will be assessed by determining plasma TRP:LNAA ratios. During Aim 2 the capacity for 4-weeks of pre-biotic RS (Potato Starch) supplementation to increase the TRPp:TRPc bacterial ratio in the gut will be determined from stool samples. Additionally, plasma TRP:LNAA ratio following acute carbohydrate consumption before and after supplementation will be determined. The scientific contribution will be to determine the impact of RS on TRPp and TRPc bacteria abundance in the gut, and how bacterial populations impact circulating TRP:LNAA levels, that can impact ENS and CNS 5HT production in humans. This contribution will be significant because it will have direct translational implications for human diseases with altered 5HT signaling.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for early_phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 28, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Last Updated

May 4, 2017

Status Verified

May 1, 2017

Enrollment Period

11 months

First QC Date

November 21, 2016

Last Update Submit

May 1, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Plasma Amino Acid Levels

    Baseline

  • Plasma Amino Acid Levels

    Following 4 weeks of supplementation

Secondary Outcomes (1)

  • Change in Plasma Amino Acid Levels

    Baseline vs. 4-weeks

Study Arms (2)

Potato Starch (Bob's Red Mill)

EXPERIMENTAL

Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.

Dietary Supplement: Potato Starch (Bob's Red Mill)

Resource ThickenUp Pregelatinized Starch

PLACEBO COMPARATOR

Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.

Dietary Supplement: Pregelatinized Starch (Resource ThickenUp)

Interventions

Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.

Potato Starch (Bob's Red Mill)

Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.

Resource ThickenUp Pregelatinized Starch

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female
  • Age 18 - 65 years old
  • Non-Obese (BMI ≤ 30 kg/m2 and \>17 kg/m2 )

You may not qualify if:

  • Urine toxicology positive,
  • Pregnant (female)
  • Alcohol intake 48 hours prior to studies,
  • Evidence of inherited disorders of lipid metabolism,
  • History of Cancer within the last 5 years,
  • Human immunodeficiency virus (HIV) antibody positive,
  • Patients with solid organ transplants,
  • Unstable angina or NY heart association class II failure or above,
  • Gastrointestinal disease specifically GI motility disorders,
  • Unstable neuropsychiatric disease including major depression/anxiety, eating disorder such as bulimia or anorexia,
  • End stage renal or hepatic disease,
  • Autoimmune disorders (e.g. SLE),
  • Prior bariatric surgery,
  • A history or current alcohol/substance abuse or nicotine containing products or illicit drugs of abuse during the preceding 6 months,
  • Treatment within one month with sedative hypnotic medications (benzodiazepines, barbiturates), or over the counter sleeping aids
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wayne State University

Detroit, Michigan, 48202, United States

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Central Study Contacts

Paul R Burghardt, PhD

CONTACT

Katlin Chappelle, BS

CONTACT

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 21, 2016

First Posted

November 28, 2016

Study Start

January 1, 2017

Primary Completion

December 1, 2017

Last Updated

May 4, 2017

Record last verified: 2017-05

Locations